Heghine Khachatryan: What EHA 2026 Reveals About the Future of Aplastic Anemia Treatment
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared American Society of Hematology’s post on LinkedIn:
“Aplastic Anemia in 2026: Moving Beyond Traditional IST
The management of severe aplastic anemia continues to evolve.
While horse ATG plus cyclosporine remains the backbone of frontline immunosuppressive therapy, recent studies and EHA 2026 discussions highlight the growing role of thrombopoietin receptor agonists (especially eltrombopag) in improving hematologic responses and reducing transfusion dependence.
Key trends shaping 2026 practice include:
- Earlier integration of TPO-receptor agonists into frontline therapy
- Improved risk stratification through molecular profiling and clonal evolution monitoring
- More individualized treatment selection based on age, donor availability, and genomic findings
- Ongoing refinement of the balance between immunosuppression and stem cell transplantation strategies
The future of aplastic anemia treatment is increasingly focused on precision medicine, deeper responses, and long-term prevention of clonal progression.”
American Society of Hematology shared a post on LinkedIn:
“How is frontline immunosuppressive therapy for aplastic anemia evolving in 2026?
Join the next Aplastic Anemia Clinical Case Webinar focusing on highlights from EHA 2026 and practical, evidence-based strategies for patient management.
June 18 | 6–7 p.m.
Register now.”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Jun 13, 2026, 15:39Ritu Verma: Recognizing Deep Vein Thrombosis Before Complications Arise
-
Jun 13, 2026, 15:09Akshat Jain: Does Mitapivat Translate to Clinical Benefit in SCD?
-
Jun 13, 2026, 14:58Olga Benítez Hidalgo: New Evidence on Marstacimab in Hemophilia Care
-
Jun 13, 2026, 14:52Sophie Georgin-Lavialle: First ERN-RITA Recommendations on USAID
-
Jun 13, 2026, 14:48Andrew Jackson: Personalized Approaches to Catheter-Related Thrombosis Prevention
-
Jun 13, 2026, 14:45Ghazaleh Bankefors: Reconnecting Across Borders and Decades at EHA 2026
-
Jun 13, 2026, 14:41Tom Langenaeken: Targeting Factor XI in Mechanical Heart Valve Thrombosis
-
Jun 13, 2026, 14:36Heghine Khachatryan: Pregnancy, Thrombosis, and Aspirin – Who Really Needs Prophylaxis?
-
Jun 13, 2026, 14:24Thomas Stauch: ITP Therapeutics Enter a New Era of Targeted Treatment